---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-011954"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-02-09T23:59:59+00:00"
generated_at: "2026-06-06T04:54:48.190235+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InMed appoints Netta Jagpal as CFO and Corporate Secretary effective Feb 20, 2024

## Summary
- Netta Jagpal appointed CFO and Corporate Secretary effective Feb 20, 2024; replaces Jonathan Tegge as Interim CFO.
- Annual base salary of CAD$325,000; eligible for annual discretionary bonus target of 40% of base salary.
- Initial grant of 50,000 stock options subject to corporate approvals under the company's stock option plan.
- Ms. Jagpal brings over 20 years of biotech finance experience from D-Wave Systems, Zymeworks, Angiotech, and Ernst & Young.

## SEC filing metadata
- accession: 0001213900-24-011954
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-02-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/ea193307-8k_inmedpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-011954
- JSON: https://secwatch.observer/filing/0001213900-24-011954.json
- Plain text: https://secwatch.observer/filing/0001213900-24-011954.txt

## Key facts
- Executive change
  Jonathan Tegge resigned as Interim Chief Financial Officer at InMed Pharmaceuticals Inc..
  - Action: resigned
  - Role: Interim Chief Financial Officer
  source text: Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company’s Interim Chief Financial Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm
- Executive change
  Netta Jagpal was appointed as Chief Financial Officer and Corporate Secretary at InMed Pharmaceuticals Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Corporate Secretary
  source text: appointed Ms. N. Netta “Neeta” Jagpal (“ Ms. Jagpal ”) ( aged 51 ) to serve, effective as of February 20, 2024 (the “ Effective Date ”), as Chief Financial Officer and Corporate Secretary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000121390024011954/0001213900-24-011954-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.